Drug Safety

, Volume 34, Issue 2, pp 93–96 | Cite as

Pharmacovigilance and the Null Hypothesis

Do We do Much for Public Health?
Editorial

References

  1. 1.
    Greener M. First do no harm: improving drug safety through legislation and independent research. EMBO Rep 2008; 9(3): 221–4PubMedCrossRefGoogle Scholar
  2. 2.
    Edwards IR. What are the real lessons from Vioxx®? Drug Saf 2005; 28(8): 651–8PubMedCrossRefGoogle Scholar
  3. 3.
    Traulsen J, Almarsdóttir AB, Björnsdóttir I. The lay user perspective on the quality of pharmaceuticals, drug therapy and pharmacy services: results of focus group discussions. Pharm World Sci 2002; 24(5): 196–200PubMedCrossRefGoogle Scholar
  4. 4.
    Gil H, Mello DF, Ferriani MG, et al. Perceptions of adolescents students on the consumption of drugs: a case study in Lima, Peru. Rev Lat Am Enfermagem 2008; 16(16): 551–7PubMedCrossRefGoogle Scholar
  5. 5.
    Bahri P. Public pharmacovigilance communication: a process calling for evidence-based, objective-driven strategies. Drug Saf 2010; 33(12): 1065–79PubMedCrossRefGoogle Scholar
  6. 6.
    Ferner R, Aronson JK. Preventability of drug-related harms — part I: a systematic review. Drug Saf 2010; 33(11): 985–94PubMedCrossRefGoogle Scholar
  7. 7.
    Issa AM, Phillips KA, Van Bebber S, et al. Drug withdrawals in the United States: a systematic review of the evidence and analysis of trends. Curr Drug Saf 2007; 2(3): 177–85PubMedCrossRefGoogle Scholar
  8. 8.
    Abraham J, Davis C. A comparative analysis of drug safety withdrawals in the UK and the US (1971–1992): implications for current regulatory thinking and policy. Soc Sci Med 2005; 61(5): 881–92PubMedCrossRefGoogle Scholar
  9. 9.
    Goldman S. Communication of medical product risk: how effective is effective enough? Drug Saf 2004; 27(8): 519–34PubMedCrossRefGoogle Scholar
  10. 10.
    Herxheimer A. Communicating with patients about harms and risks. PloS 2005; 2(2): e42CrossRefGoogle Scholar
  11. 11.
    Hugman B, Edwards IR. The challenge of effectively communicating patient safety information. Expert Opin Drug Saf 2006; 5(4): 495–9PubMedCrossRefGoogle Scholar
  12. 12.
    Meyboom R. The case for good pharmacovigilance practice. Pharmacoepidemiol Drug Saf 2000; 9(4): 335–6PubMedCrossRefGoogle Scholar
  13. 13.
    Pietrek M, Coulson R, Czarnecki A. Good pharmacovigilance practice: the way forward? Drug Inf J 2009; 43: 500–9CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2011

Authors and Affiliations

  1. 1.Uppsala Monitoring CentreUppsalaSweden
  2. 2.University of Benin School of MedicineBeninNigeria

Personalised recommendations